newsfilter
← Latest News
Business Wire·

Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich's Ataxia

FRIEDREICH'S ATAXIA IS AN ULTRA-RARE, PROGRESSIVE, NEUROMUSCULAR DISEASE THAT AFFECTS APPROXIMATELY 5,000 DIAGNOSED PATIENTS IN THE UNITED STATES SKYCLARYS IS INDICATED FOR THE TREATMENT OF FRIEDREICH'S ATAXIA IN